Brainomix has raised an additional 4.8 million pounds ($6.5 million) to extend its series C financing to 18.8 million pounds ($25.4 million), with the funds earmarked for U.S. and European Union (EU) expansion and product development.
The round was led by existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, with participation from new U.S.-based investor Modi Ventures.
The additional funding will support deployment of its Brainomix 360 Stroke and e-Lung imaging platforms across healthcare facilities in the U.S. and the EU, according to Brainomix.
Brainomix 360 Stroke, an AI imaging tool for stroke care, and e-Lung, for lung fibrosis diagnosis, are both U.S. Food and Drug Administration-cleared, the firm added.
